Patient description: A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow: A wellbeing, well-nourished man, non-icteric, cooperative and alert Weight: 73 kg Height: 177 BP: 120/80 HR: 90/min RR: 22/min Hgb: 13 g/dl WBC: 8000 /mm3 (Neutrophil: 2700/mm3) Plt: 300000 /ml AST: 40 U/L ALT: 56 U/L Alk P: 147 U/L Bill total: 1.2 mg/dl ESR: 120 mm/hr MPO-ANCA: 153 EU

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atypical; Mycobacterium, Pulmonary, Tuberculous The patient and/or legal representative of the patient has provided a written informed consent before in the study The patient is aged 18 or older The patient has signs of functional respiratory (cough, sputum, hemoptysis, dyspnea, chest pain and / or general signs (asthenia and / or anorexia and / or weight loss) The patient has a creatinine clearance above 30 ml / min The patient underwent a thoracic scan not older than one month before the first positive bacteriological sample The patient underwent a bronchoscopy with sampling conducted in the territory corresponding to the radiographic The most plausible alternative diagnostics have been eliminated using the thoracic scan and bronchoscopy The patient has at least two positive cultures for M. xenopi sputum collected on two separate days AND/OR a positive culture for M. xenopi in a bronchoalveolar lavage or bronchial aspiration directed AND / OR transbronchial biopsy or lung biopsy with surgical histology for a mycobacterial infection (granuloma or Ziehl positive) and a culture positive M. xenopi, AND / OR biopsy with histology compatible with mycobacteriosis and one or more positive sputum culture for M . xenopi The patient is willing and able to take the study treatment throughout the duration If this is a woman of childbearing age, the patient is ready to use for the duration of the test contraception method other than estrogen-progestin  Hypersensitivity to any of the molecules (rifampicin, ethambutol, moxifloxacin, clarithromycin) Any patient with a relapse of a lung infection with M. xenopi The patient is treated with molecules that can interfere with cytochrome P450 and can not be replaced by another therapeutic class The patient is treated by prolonging the QT molecules which can not be replaced by another therapeutic class The patient is treated with alkaloid of ergot, cisapride, biperidil, pimozide, mizolastine The patient has heart failure with left ventricular ejection fraction below 30% Discovered on the balance sheet or history, we find that the patient infection with human immunodeficiency virus HIV 1 and 2 a long QT on ECG and / or arrhythmias or clinically significant bradycardia judged by the investigator cytolysis with transaminases increase more than 5 times normal renal failure with creatinine clearance below 30 ml / min The patient has cirrhosis Child Pugh C and / or porphyria There pregnancy or during breastfeeding The patient has an inability to meet the protocol requirements, including active substance abuse, according to the investigator